Partnering

At Simris, we follow a collaboration-driven strategy to commercialise our proprietary Antibody Drug Conjugate (ADC) payloads through licensing partnerships.

We welcome collaborations with academic institutions, CDMOs, and biopharma companies seeking next-generation payload solutions.

We are particularly interested in partners with expertise in ADC development, regulatory advancement, and commercialisation.

These partnerships represent a key growth engine for Simris and a major opportunity to unlock shareholder value.